3 results
Approved WMOPending
To assess the long-term safety and tolerability of 35 mg and 70 mg RVT-101 in subjects with DLB
Approved WMOCompleted
Primary• To assess the effects of RVT-101 versus placebo on global function as measured by the Clinician*s Interview-Based Impression of Change Plus Caregiver Input (CIBIC+) after 24 weeks of treatment• To assess the effects of RVT-101 versus…
Approved WMOCompleted
The primary study objective is to compare the rate of major CIED infections through 12-months post-implant between the TYRX envelope group and the control group.